{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:04:20Z","timestamp":1772881460840,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Dyskeratosis congenita is a rare inherited disease with classic cutaneous symptoms, sometimes accompanied with more severe extracutaneous manifestations such as bone marrow failure, which can be lethal. Eltrombopag is an orally available thrombopoietin receptor agonist in clinical use for increasing platelet levels in patients with immune thrombocytopenia and aplastic anemia. Here, 3 pediatric patients with dyskeratosis congenita are presented with varying disease severity, in which off-label eltrombopag treatment had no clinical effect on bone marrow failure. This, in addition to the negative results in a previous case report, supports the preclusion of eltrombopag use in dyskeratosis congenita.<\/jats:p>","DOI":"10.1097\/mph.0000000000002775","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:02:56Z","timestamp":1698364976000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Severe Thrombocytopenia Due to Bone Marrow Failure in Children With Dyskeratosis Congenita Does Not Respond to Eltrombopag Treatment: Case Series"],"prefix":"10.1097","volume":"46","author":[{"given":"Lotta","family":"Pramanik-Jonsson","sequence":"first","affiliation":[{"name":"Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet"},{"name":"Section of Pediatric Hematology, Immunology and HCT, Astrid Lindgren Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Borss\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medical Biosciences, Ume\u00e5 University"},{"name":"Section of Pediatric Hematology and Oncology, Child and Adolescent Medical Center, University Hospital of Ume\u00e5, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Vonlanthen","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine, Medical Diagnostics Center, Karolinska University Hospital, Stockholm"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Medical Biosciences, Ume\u00e5 University"},{"name":"Section of Pediatric Hematology and Oncology, Child and Adolescent Medical Center, University Hospital of Ume\u00e5, Ume\u00e5, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Sundin","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet"},{"name":"Section of Pediatric Hematology, Immunology and HCT, Astrid Lindgren Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"R1-20250804","first-page":"56","article-title":"Dyskeratosis congenita","volume":"15","author":"Kumar","year":"2013","journal-title":"JK Science"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mrfmmm.2011.06.008","article-title":"Dyskeratosis congenita as a disorder of telomere maintenance","volume":"730","author":"Nelson","year":"2012","journal-title":"Mutat Res"},{"key":"R3-20250804","first-page":"943","article-title":"Dyskeratosis congenita: a literature review","volume":"18","author":"AlSabbagh","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2000.02109.x","article-title":"Dyskeratosis congenita in all its forms","volume":"110","author":"Dokal","year":"2000","journal-title":"Br J Haematol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1399-3038.2010.01136.x","article-title":"Dyskeratosis congenita: a combined immunodeficiency with broad clinical spectrum\u2014a single-center pediatric experience","volume":"22","author":"Jyonouchi","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/17474086.2019.1662720","article-title":"An update on the biology and management of dyskeratosis congenita and related telomere biology disorders","volume":"12","author":"Niewisch","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2022.2108784","article-title":"The biology and management of dyskeratosis congenita and related disorders of telomeres","volume":"15","author":"Tummala","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood-2018-03-837799","article-title":"Homozygous OB-fold variants in telomere protein TPP1 are associated with dyskeratosis congenita\u2013like phenotypes","volume":"132","author":"Tummala","year":"2018","journal-title":"Blood"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-019-01159-0","article-title":"Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation","volume":"79","author":"Fattizzo","year":"2019","journal-title":"Drugs"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098618769587","article-title":"Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety","volume":"9","author":"Gonzalez-Porras","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2040620717693573","article-title":"From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag","volume":"8","author":"Gill","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1160\/TH12-02-0121","article-title":"Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia","volume":"108","author":"Trautmann","year":"2012","journal-title":"Thromb Haemost"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/bloodadvances.2017010660","article-title":"Eltrombopag for use in children with immune thrombocytopenia","volume":"2","author":"Kim","year":"2018","journal-title":"Blood Adv"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"e29066","DOI":"10.1002\/pbc.29066","article-title":"Eltrombopag in children with severe aplastic anemia","volume":"68","author":"Lesmana","year":"2021","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:03:51Z","timestamp":1754337831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002775","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"2023-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}